News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

First Patient Dosed in the Phase I/II Study of Umecrine Mood’s Candidate Drug for Premenstrual Dysphoric Disorder


5/23/2013 10:00:39 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

STOCKHOLM – May 23, 2013. Umecrine Mood AB announced today that dosing has been initiated in a randomized Phase I/II study of UC1010 for the treatment of patients with premenstrual dysphoric disorder (PMDD). Umecrine Mood is part of the Karolinska Development portfolio.

Help employers find you! Check out all the jobs and post your resume.

Read at GlobeNewswire

Related News

comments powered by Disqus
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES